Prognostic significance of apoptotic index in multiple myeloma patients treated by conventional therapy and novel agents, thalidomide and bortezomib

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F09%3A00009796" target="_blank" >RIV/61989592:15110/09:00009796 - isvavai.cz</a>

Result on the web

—

DOI - Digital Object Identifier

—

Result language

angličtina

Original language name

Prognostic significance of apoptotic index in multiple myeloma patients treated by conventional therapy and novel agents, thalidomide and bortezomib

Original language description

Objective: To assess the outcome of the measurement of apoptotic index in myeloma patients treated by conventional chemotherapy and novel drugs with biological mechanism of action, thalidomide and bortezomib. Patients and methods: In a cohort of 189 patients with newly diagnosed multiple myeloma from November 1997 through February 2008, we assessed the prognostic significance of plasma cell apoptotic index (PC-AI) using annexin-V. The whole group was subsequently divided according to treatment approach(conventional chemotherapy only vs. inclusion of novel drugs, thalidomide and bortezomib), and curves of overall survival were constructed. Results: In the whole group (n=189), low levels of PC-AI<4.5% significantly separeted patients with unfavorable prognosis (median OS 16 vs. 38 months, P=0.004). In patients treated with conventional chemotherapy only (n=139) the results were similar (median OS 10 vs. 25 months, P=0,02), and the apoptotic index maintained its significance even within

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

<a href="/en/project/NR9500" target="_blank" >NR9500: Angiogenesis, plasma cell kinetics, parameters of microenvironments of bone marrow and bone metabolism in monoclonal gammopathy of undetermined significance and initial phases of multiple myeloma</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2009

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

European Journal of Haematology

ISSN

0902-4441

e-ISSN

—

Volume of the periodical

83

Issue of the periodical within the volume

6

Country of publishing house

GB - UNITED KINGDOM

Number of pages

7

Pages from-to

—

UT code for WoS article

—

EID of the result in the Scopus database

—